Related Experiment Videos
New biologic immunosuppressive agents in transplantation
1Department of Internal Medicine, University of Michigan, Ann Arbor 48109-0676.
Current Opinion in Nephrology and Hypertension
|November 1, 1994
Summary
Inducing immunologic tolerance to alloantigens is key in transplantation. Blocking T-cell activation signals, particularly through CD28 costimulation, offers promising strategies for achieving this tolerance.
Area of Science:
- Immunology
- Transplantation Science
- Cellular Biology
Background:
- Achieving antigen-specific immunologic nonresponsiveness (tolerance) to alloantigens is a critical goal in transplantation.
- Current strategies primarily focus on modulating T-cell responses.
Purpose of the Study:
- To review novel strategies for inducing tolerance to alloantigens by targeting T-cell activation signals.
- To highlight promising biologic agents that block T-cell costimulatory pathways.
Main Methods:
- Review of recent advances in understanding T-cell receptor-major histocompatibility complex interactions.
- Analysis of mechanisms underlying self-tolerance.
- Evaluation of costimulatory receptors and their ligands in T-cell activation.
Main Results:
- T-cell activation requires two signals: antigen engagement (Signal 1) and costimulation (Signal 2), often via CD28.
- Blocking either Signal 1 or Signal 2 can induce alloantigen tolerance.
- New biologic agents targeting these signals are emerging as promising therapeutic modalities.
Conclusions:
- Targeting T-cell activation signals, especially costimulatory pathways, represents a significant advancement in transplantation tolerance induction.
- Further research into these novel strategies holds potential for improving transplant outcomes.